Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adult patients with advanced SM, including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL).